JPH05163134A - Cosmetic - Google Patents

Cosmetic

Info

Publication number
JPH05163134A
JPH05163134A JP35386191A JP35386191A JPH05163134A JP H05163134 A JPH05163134 A JP H05163134A JP 35386191 A JP35386191 A JP 35386191A JP 35386191 A JP35386191 A JP 35386191A JP H05163134 A JPH05163134 A JP H05163134A
Authority
JP
Japan
Prior art keywords
cells
medium
extract
solution
lactic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP35386191A
Other languages
Japanese (ja)
Inventor
Masayuki Iwata
雅之 岩田
Kenta Tabuchi
健太 田淵
Ryoji Kodaira
了二 小平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dowa Holdings Co Ltd
Original Assignee
Dowa Mining Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dowa Mining Co Ltd filed Critical Dowa Mining Co Ltd
Priority to JP35386191A priority Critical patent/JPH05163134A/en
Publication of JPH05163134A publication Critical patent/JPH05163134A/en
Pending legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)

Abstract

PURPOSE:To obtain a cosmetic having excellently beautifying effects on skin, sufficient shelf stability and high safety. CONSTITUTION:First, kefia granules are inoculated into 10% reduced defatted milk, subjected to subculture every day at 20 deg.C and activated. The activated kefia granules are cultured by using a medium for separating cells of lactic acid bacteria of the genus Lactobacillus and the cells of lactic acid bacteria of the genus Lactobacillus are separated. Then, the cells are inoculated into a medium, subjected to stationary culture or mild spinner culture at 20-35 deg.C and the culture solution is centrifuged to collect cells. 1 pt.wt. of the cells is extracted with 2-10 pts.wt. solvent at 0-40 deg.C for 1-24 hours, the obtained filtrate is concentrated to give a cell extract (extracted solution). A cosmetic is blended with 0.01-0.5% of the extract as an active ingredient.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、優れた皮膚美白効果お
よび活性酸素消去効果を有する乳酸菌の培養菌体抽出物
を配合した化粧料に関するものである。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a cosmetic composition containing an extract of cultured lactic acid bacteria having excellent skin whitening effect and active oxygen scavenging effect.

【0002】[0002]

【従来の技術】日焼けによる色黒、シミ、ソバカス等
は、黒褐色無定形の色素であるメラニンの生成により生
じるものと考えられており、このメラニンは、皮膚が紫
外線などの外的刺激を受けると、皮膚のメラニン細胞中
に存在するチロシナーゼ(チロシン酸化酵素)が活性化
し、たんぱく質構成アミノ酸の一種であるチロシンが酸
化されて生成する。したがって、メラニン生成に関与す
るチロシナーゼの活性を抑制することにより肌を白くす
る効果が期待されるため、チロシナーゼ活性抑制成分の
化粧料への配合が提唱されていた。
2. Description of the Related Art It is believed that dark skin, spots, freckles, etc. due to sunburn are caused by the production of melanin, which is a dark brown amorphous pigment, and this melanin is produced when the skin receives external stimuli such as ultraviolet rays. , Tyrosinase (tyrosine oxidase) present in melanocytes of the skin is activated, and tyrosine, which is one of the protein-constituting amino acids, is oxidized and produced. Therefore, since the effect of whitening the skin is expected by suppressing the activity of tyrosinase involved in melanin production, the incorporation of a tyrosinase activity suppressing component into cosmetics has been proposed.

【0003】従来、美白効果を有する化粧料として、特
公昭55−43443号「美白化粧料」や特公昭54−
974号「生薬抽出物配合組成物」に開示されるよう
に、アスコルビン酸またはその誘導体を配合したものが
知られている。他にも、アルブチンを配合した皮膚外用
剤(特開昭60−16906号等)やコウジ酸を配合し
た漂白化粧料(特公昭32−8100号)、植物成分
(特開昭63−2913号他)または動物成分(特開昭
63−8312号他)から抽出した化粧料が美白効果を
有するものとして公知である。
Conventionally, as cosmetics having a whitening effect, JP-B-55-43443, "Whitening cosmetics" and JP-B-54-
As disclosed in Japanese Patent No. 974, "Composition containing crude drug extract," a composition containing ascorbic acid or a derivative thereof is known. In addition, external skin preparations containing arbutin (JP-A-60-16906, etc.), bleaching cosmetics containing kojic acid (JP-B-32-8100), plant components (JP-A-63-2913, etc.) ) Or an animal ingredient (Japanese Patent Laid-Open No. 63-8312, etc.) is known to have a whitening effect.

【0004】しかしながら、上記従来の化粧料は、充分
な美白効果が認められないものが多く、また、保存安定
性が充分でなかったり、刺激性を有するなど皮膚に対す
る安全性に問題があるものも多かった。
However, many of the above-mentioned conventional cosmetics do not have a sufficient whitening effect, and also have some problems such as insufficient storage stability and irritation, which are problematic to the skin. There were many.

【0005】[0005]

【発明が解決しようとする課題】本発明は、上述従来の
技術の問題点を解決し、優れた皮膚美白効果を有し、か
つ充分な保存安定性および高い安全性を有する化粧料を
提供することを目的とする。
DISCLOSURE OF THE INVENTION The present invention solves the above-mentioned problems of the prior art and provides a cosmetic having an excellent skin whitening effect, sufficient storage stability and high safety. The purpose is to

【0006】[0006]

【課題を解決するための手段】本発明者等は斯る課題を
解決するため鋭意研究した結果、ケフィア粒より分離し
たラクトバチルス属に属する乳酸菌の菌体抽出物が、チ
ロシナーゼ活性抑制効果、メラニン生成抑制効果および
活性酸素消去効果を兼ね備え、優れた美白効果を発揮す
ることを見い出し、本発明を提供することができた。
Means for Solving the Problems The inventors of the present invention have conducted extensive studies to solve such problems, and as a result, a lactic acid bacterium cell extract isolated from Kefir grains belonging to the genus Lactobacillus has an inhibitory effect on tyrosinase activity, melanin. It has been found that it has an effect of suppressing generation and an effect of eliminating active oxygen, and exhibits an excellent whitening effect, and was able to provide the present invention.

【0007】すなわち、本発明は、ケフィア粒から分離
したラクトバチルス属乳酸菌の菌体抽出物を配合したこ
とを特徴とする化粧料に関するものである。
[0007] That is, the present invention relates to a cosmetic composition containing a lactic acid bacterium extract of Lactobacillus separated from kefir grains.

【0008】[0008]

【作用】本発明の化粧料は、以下のような方法で製造す
ることができる。
The cosmetic of the present invention can be manufactured by the following method.

【0009】まず、ケフィア粒を10%還元脱脂乳に接種
し、20℃で毎日植え継いで活性化させる。次いで、この
活性化ケフィア粒をラクトバチルス属乳酸菌体分離用培
地を用いて培養し、ラクトバチルス属乳酸菌体(培養し
た際にガスを産出しないホモ醗酵型乳酸菌の任意の菌
体)を分離する。なお、ラクトバチルス属乳酸菌体分離
用培地としては、たとえば乳酸菌の培養の際に一般的に
用いられるRogosaの培地(Eftymiou, C, and Hansen,
P.A. 1962 Journal of Infectious Disease 110,p. 258
- 267) の組成のうち、炭素源をブドウから糖乳糖に代
えた培地(以後L-Rogosa培地と略す)を用いることがで
きる。
First, 10% reconstituted skim milk is inoculated with kefir grains and subcultured at 20 ° C. every day for activation. Then, the activated kefir grains are cultured using a medium for separating lactic acid bacterium of the genus Lactobacillus to separate the lactic acid bacterium of the genus Lactobacillus (arbitrary bacterium of homofermentative lactic acid bacterium that does not produce gas when cultured). As a medium for separating Lactobacillus cells from Lactobacillus, for example, Rogosa's medium (Eftymiou, C, and Hansen,
PA 1962 Journal of Infectious Disease 110, p. 258
-267), a medium in which the carbon source is changed from glucose to lactose (hereinafter abbreviated as L-Rogosa medium) can be used.

【0010】次に、上記のようにしてケフィア粒から分
離した菌体を培地に接種し、20℃ないし35℃の温度で静
置培養あるいは緩やかな撹拌培養を行う。培養後、得ら
れた培養液を遠心分離するなどして菌体を集める。集め
られた培養菌体は、そのまま直ちに次に述べる抽出操作
に供してもよく、あるいは、凍結、凍結乾燥などを行い
保存することもできる。なお、ラクトバチルス属乳酸菌
の培養の際に用いる培地としては、例えばRogosaの培地
など、使用菌が生育し得る培地を使用することができ
る。
Next, the cells separated from the kefir grains as described above are inoculated into the medium, and static culture or gentle stirring culture is carried out at a temperature of 20 ° C to 35 ° C. After culturing, cells are collected by centrifuging the obtained culture solution. The collected cultured bacterial cells may be directly subjected to the extraction operation described below as they are, or may be stored after being frozen or lyophilized. As a medium used for culturing Lactobacillus of genus Lactobacillus, for example, a medium capable of growing the used bacterium, such as Rogosa's medium, can be used.

【0011】次いで、生菌体、凍結後融解した菌体、ま
たは乾燥菌体1重量部または1容量部に対して、溶剤を
2〜10重量部または 2〜10容量部加え、 0〜40℃にて 1
〜24時間抽出を行い、得られた濾液を濃縮することによ
って目的の菌体抽出物(抽出液)を得る。なお、上記溶
剤としては、低級アルキルアルコール(メタノール、ニ
タノール、インプロパノール)および水の単独液または
これらの2種以上の混合液を使用することができる。ま
た、上記菌体抽出物(抽出液)は、必要に応じてさらに
濃縮・乾燥することにより固形抽出物とすることもでき
る。
Then, a solvent is added to 1 part by weight or 1 part by volume of live cells, cells that have been thawed after freezing, or dried cells.
Add 2 to 10 parts by weight or 2 to 10 parts by volume, and add at 0 to 40 ° C 1
Extraction is performed for -24 hours, and the obtained filtrate is concentrated to obtain the target cell extract (extract). As the solvent, a lower alkyl alcohol (methanol, nitanol, inpropanol) and water alone or a mixture of two or more of these can be used. In addition, the above-mentioned bacterial cell extract (extract) may be further concentrated and dried, if necessary, to give a solid extract.

【0012】このようにして得た菌体抽出物は、チロシ
ナーゼ活性抑制効果、メラノーマ細胞におけるメラニン
生成抑制効果、および活性酸素消去効果を有することが
本発明者等によって確認されており、この抽出物を有効
成分として0.01〜 5%配合することにより、美白効果な
らびに活性酸素消去効果を有する化粧料を得ることがで
きる。
It has been confirmed by the present inventors that the bacterial cell extract thus obtained has an effect of suppressing tyrosinase activity, an effect of suppressing melanin production in melanoma cells, and an effect of eliminating active oxygen. By blending 0.01 to 5% as an active ingredient, a cosmetic having a whitening effect and an active oxygen scavenging effect can be obtained.

【0013】以下、実施例により本発明をさらに詳細に
説明する。しかし本発明の範囲は以下の実施例により制
限されるものではない。
Hereinafter, the present invention will be described in more detail with reference to examples. However, the scope of the present invention is not limited by the following examples.

【0014】[0014]

【実施例】【Example】

(1)ケフィア粒からラクトバチルス属乳酸菌の分離。 (1) Isolation of lactic acid bacteria of the genus Lactobacillus from kefir grains.

【0015】まず、クリスチャン・ハンセン社(デンマ
ーク・コペンハーゲン)より入手したケフィア粒を、 1
05℃で20分殺菌した10%還元脱脂乳に接種し、20〜22℃
で毎日植え継ぎ、ケフィア粒を活性化させた。次いで、
活性化したケフィア粒約 2gを滅菌した乳鉢に採取し、
これに炭素源としてブドウ糖の代わりに乳糖を用いたRo
gosaの培地(以下L-Rogosa培地と略す)2ml を加え、ケ
フィア粒を十分に摩砕した。
First, 1 kefir grain obtained from Christian Hansen (Copenhagen, Denmark)
Inoculate 10% reduced skim milk sterilized at 05 ℃ for 20 minutes at 20-22 ℃
Each day, the seeds were subcultured to activate the kefir grains. Then
Collect about 2 g of activated kefir grains in a sterilized mortar,
Ro which used lactose as a carbon source instead of glucose
2 ml of gosa medium (hereinafter abbreviated as L-Rogosa medium) was added, and kefir grains were thoroughly ground.

【0016】次に、微細化したケフィア粒を含む懸濁液
をL-Rogosaの培地で10段階に希釈し、適当な希釈段階の
希釈液 0.1mlをあらかじめ作製しておいてたRogosa寒天
培地(寒天濃度 1.5%)上にコンラージ棒を用いて塗布
した。次いで、この寒天培地をガスパックジャーを用い
て30℃で4日間嫌気的に培養した。培養後、光学顕微鏡
を用いて生じたコロニーの中から長桿菌状を示す菌を約
20個分離し、これらの菌をそれぞれ新たなL-Rogosa寒天
培地を用いてシングルコロニーアイソレーションを3回
繰り返して純化した。
Next, the suspension containing the finely divided kefir grains was diluted with L-Rogosa medium in 10 steps, and 0.1 ml of a diluent at an appropriate dilution step was prepared in advance in Rogosa agar medium ( Agar concentration of 1.5%) was applied to the agar using a conradi stick. Then, this agar medium was anaerobically cultured at 30 ° C. for 4 days using a gas pack jar. After culturing, from the colonies generated by using an optical microscope, about
Twenty cells were separated, and each of these bacteria was purified by repeating single colony isolation three times using a new L-Rogosa agar medium.

【0017】純化後、得られた分離株の液体培養時にお
ける性質を調べるため、各菌株をネジ栓付き試験管中の
L-Rogosa液体培地に接種し、密栓後30℃で24〜48時間静
置培養し、培養終了時にガスの産出が認められない株を
選択した。本実施例では、このようにして得た数株のう
ちの任意の1株を代表株R202として用いることにした。
After purification, each strain was tested in a test tube with a screw stopper in order to investigate the properties of the obtained isolate during liquid culture.
L-Rogosa liquid medium was inoculated, and after hermetically sealing, static culture was performed at 30 ° C for 24 to 48 hours, and a strain that did not produce gas at the end of the culture was selected. In this example, any one of several strains thus obtained was used as the representative strain R202.

【0018】R202株の菌学的性質は下記の通りであっ
た。形態 ・細胞の大きさ ‥‥1 〜1.2 ×5 〜20μm ・形状 ‥‥桿状 ・運動性 ‥‥なし ・胞子の有無 ‥‥なし ・グラム染色 ‥‥陽性培地における生育状態 (ガスパック法により、L-Rogosa寒天平板培地表面で30
℃、4日間培養した場合におけるコロニーの性状) ・形状 ‥‥円形 ・大きさ ‥‥直径 0.5〜3 mm ・色調 ‥‥白色生理学的性質 ・硝酸塩の還元 ‥‥なし ・色素の生成 ‥‥なし ・カタラーゼ ‥‥陰性 ・生育範囲 ‥‥温度:20〜35℃、pH: 5.0〜
6.5 ・酸素に対する態度‥‥通性嫌気性 なお、上記の菌学的性質を示す菌株(R202株)は、工業
技術院微生物工業研究所(微工研)に微工研菌寄第 126
24号として寄託した。
The bacteriological properties of the R202 strain were as follows. Morphology / Cell size ・ ・ ・ 1 〜 1.2 × 5 〜 20 μm ・ Shape ‥ Rod-like ・ Motility ‥‥‥ None ・ Presence or absence of spores ‥ None ・ Gram stain ‥‥ Growth state in positive medium (L by gas pack method) -30 on Rogosa agar plate surface
Properties of colonies after culturing at 4 ° C for 4 days) ・ Shape ・ ・ ・ Circle ・ Size ・ ・ ・ diameter 0.5 to 3 mm ・ Color tone ・ ・ ・ Physical properties・ Reduction of nitrate ・ ・ ・ None ・ Dye formation ・ ・ ・ None ・Catalase: Negative ・ Growth range: Temperature: 20-35 ℃, pH: 5.0-
6.5 ・ Attitude toward oxygen: facultative anaerobic Note: The strain (R202 strain) that exhibits the above-mentioned mycological properties was sent to the Institute of Microbiology, Institute of Industrial Science and Technology (Microtechnical Laboratory).
Deposited as No. 24.

【0019】(2)ラクトバチルス属乳酸菌体抽出物の
調製 まず、以下に示す(A)の組成で基礎培地、および
(B)の組成で乳糖水溶液を調製し、120 ℃で20分間、
別々に高圧滅菌した。 (A) ペプトン(極東製薬製) 200 (g) 粉末酵母エキス(極東製薬製) 100 (g) リン酸1カリウム 5 (g) リン酸2カリウム 5 (g) クエン酸3アンモニウム 10 (g) 酢酸ナトリウム(無水) 10 (g) コハク酸ナトリウム 5 (g) ツィーン80 5 (g) MgSO4 ・7H2 O 2.3 (g) MnSO4 ・(4〜6)H2 O 0.48 (g) FeSO4 ・7H2 O 0.14 (g) 蒸留水 4 (l) (B) 乳糖 500 (g) 蒸留水 6 (l)
(2) Preparation of Lactobacillus sp. Lactobacillus Extract First, a basal medium having the composition (A) and an aqueous lactose solution having the composition (B) shown below are prepared, and at 120 ° C for 20 minutes.
Separately autoclaved. (A) Peptone (Kyokuto Pharmaceutical) 200 (g) Powdered yeast extract (Kyokuto Pharmaceutical) 100 (g) 1 potassium phosphate 5 (g) 2 potassium phosphate 5 (g) 3 ammonium citrate 10 (g) acetic acid sodium (anhydrous) 10 (g) sodium succinate 5 (g) Tween 80 5 (g) MgSO 4 · 7H 2 O 2.3 (g) MnSO 4 · (4~6) H 2 O 0.48 (g) FeSO 4 · 7H 2 O 0.14 (g) Distilled water 4 (l) (B) Lactose 500 (g) Distilled water 6 (l)

【0020】滅菌後、上記基礎培地と乳糖水溶液とを混
合し、L-Rogosa液体培地で前培養しておいたR202株の培
養液 100mlを接種し、30℃で5日間緩やかに撹拌(100r
pm)しながら培養した。なお、培養開始後24時間目から
は、20%炭酸ナトリウム水溶液(高圧滅菌済み)を用い
てpH 5.6の中和培養を行った。培養終了後、遠心分離
(5,000×g 、15分間)によって菌体を集め、集めた菌体
を生理食塩水で洗浄した後、再び遠心分離によって菌体
を集め、500ml の蒸留水に懸濁し、−20℃のフリーザー
で1夜凍結保存した。
After sterilization, the above basal medium and lactose aqueous solution were mixed, and 100 ml of the culture solution of the R202 strain pre-cultured in L-Rogosa liquid medium was inoculated and gently stirred at 30 ° C. for 5 days (100 r
pm) while culturing. From 24 hours after the start of the culture, neutralization culture of pH 5.6 was performed using a 20% sodium carbonate aqueous solution (high pressure sterilized). Centrifuge after culturing
(5,000 xg for 15 minutes), collect the cells, wash the collected cells with physiological saline, centrifuge again to collect the cells, suspend them in 500 ml of distilled water, and use a freezer at -20 ° C. It was stored frozen overnight.

【0021】次に、凍結した菌体懸濁液を室温で融解
後、全量1リットル、終エタノール濃度20%となるよう
に、エタノールと蒸留水を加え、25℃で緩やかに撹拌(1
00rpm)しながら24時間抽出を行った。抽出後、得られた
抽出液を遠心分離して大部分の菌体を除き、その上澄液
を1回濾過して約 900mlの濾液を得た。次いで、この濾
液をエバポレーターによって減圧濃縮し、約50mlの濃縮
液を得た。得られた濃縮液は、透析チューブに入れて約
1リットルの蒸留水中で1夜(4℃)透析を行った。透析
後、透析外液をエバポレーターによって減圧濃縮し、50
mlの濃縮液(R202株の菌体抽出物)を得た。
Next, after the frozen cell suspension was thawed at room temperature, ethanol and distilled water were added so that the total amount was 1 liter and the final ethanol concentration was 20%, and the mixture was gently stirred (1
The extraction was performed for 24 hours while (00 rpm). After the extraction, the obtained extract was centrifuged to remove most of the cells, and the supernatant was filtered once to obtain about 900 ml of filtrate. Then, this filtrate was concentrated under reduced pressure by an evaporator to obtain a concentrated liquid of about 50 ml. The concentrate thus obtained was placed in a dialysis tube and dialyzed overnight (4 ° C.) in about 1 liter of distilled water. After dialysis, the external dialysate was concentrated under reduced pressure using an evaporator, and
Thus, a concentrated solution (ml extract of R202 strain) was obtained in ml.

【0022】(3)ラクトバチルス属乳酸菌体抽出物の
チロシナーゼ活性抑制率の測定試験まず、試験管に100
mMコハク酸ナトリウム緩衝液(pH5.5) 1.8ml、270 uni
ts/mlマッシュルームチロシナーゼ溶液(シグマ社製)
0.1ml 、および試料溶液(
(3) Measurement test of tyrosinase activity inhibitory rate of Lactobacillus lactic acid bacterium extract First, 100
mM sodium succinate buffer (pH 5.5) 1.8 ml, 270 uni
ts / ml mushroom tyrosinase solution (manufactured by Sigma)
0.1 ml, and sample solution (

【0023】(2)で得たR202株の菌体抽出物)0.1ml
を入れて混合し、30℃の恒温水層で15分間インキュベー
トした。次いで、この試験管に6 mM L-DOPA 溶液(和光
純薬工業製:上記100 mMコハク酸ナトリウム緩衝液に溶
解したもの)1mlを加えて撹拌した。撹拌後、この試験
管を30℃の恒温室中に設置した往復振とう機に約45°傾
けてセットし、40分間振とう(往復回数150/分)した。
振とう後、分光光度計を用いて 475nmの吸光度を測定
し、その測定値をAとした。
0.1 ml of the R202 strain cell extract obtained in (2)
Were mixed with each other and incubated in a constant temperature water layer at 30 ° C. for 15 minutes. Then, 1 ml of a 6 mM L-DOPA solution (manufactured by Wako Pure Chemical Industries: dissolved in the above 100 mM sodium succinate buffer) was added to this test tube and stirred. After stirring, the test tube was set on a reciprocal shaker installed in a thermostatic chamber at 30 ° C. with a tilt of about 45 °, and shaken for 40 minutes (reciprocating frequency 150 / min).
After shaking, the absorbance at 475 nm was measured using a spectrophotometer, and the measured value was designated as A.

【0024】一方、対照として、試料溶液の代わりに上
記コハク酸ナトリウム緩衝液を加えたこと以外は上記と
同様にして 475nmの吸光度を測定し、その測定値をBと
し、また、L-DOPA溶液の代わりに上記コハク酸ナトリウ
ム緩衝液を加えたこと以外は上記と同様にして 475nmの
吸光度を測定し、その測定値をCとした。
On the other hand, as a control, the absorbance at 475 nm was measured in the same manner as above except that the sodium succinate buffer solution was added instead of the sample solution, and the measured value was designated as B, and the L-DOPA solution was used. The absorbance at 475 nm was measured in the same manner as above except that the sodium succinate buffer solution was added instead of the above, and the measured value was designated as C.

【0025】上記 475nmの吸光度の測定値から試料溶液
のチロシナーゼ活性抑制率を算出した。なお、チロシナ
ーゼ活性抑制率の算出は、以下の計算式を用いて行い、
その結果を表1に示した。 チロシナーゼ活性抑制率(%)={1−(A−C)/
B}×100
The tyrosinase activity inhibition rate of the sample solution was calculated from the measured value of the absorbance at 475 nm. The calculation of the tyrosinase activity suppression rate is performed using the following calculation formula,
The results are shown in Table 1. Tyrosinase activity inhibition rate (%) = {1- (AC) /
B} × 100

【表1】 [Table 1]

【0026】(4)ラクトバチルス属乳酸菌体抽出物の
B16メラノーマ細胞におけるメラニン生成抑制効果測定
試験 まず、メラニンを生成するマウス由来の悪性黒色腫細胞
である B16メラノーマ細胞(B16-F0、ATCC No. CRL-632
2)を、ウシ胎児血清を終濃度10%となるように添加した
イーグルMEM培地で培養し、6ウェルプレート(FALC
ON)の各ウェルに、該細胞を 3×103 /ml の濃度で含む
上記培地を 6ml入れ、CO2 インキュベーター(5 %C
2 、37℃)内で5日間培養した。
(4) Lactobacillus lactic acid bacterium extract
B16 Melanoma Cell Inhibitory Effect Measurement Test First, B16 melanoma cells (B16-F0, ATCC No. CRL-632), which are mouse-derived malignant melanoma cells that produce melanin.
2) was cultured in Eagle's MEM medium supplemented with fetal bovine serum to a final concentration of 10%, and then cultured in a 6-well plate (FALC
6 ml of the above medium containing the cells at a concentration of 3 × 10 3 / ml was put into each well of (ON), and CO 2 incubator (5% C
The cells were cultured in O 2 at 37 ° C. for 5 days.

【0027】次いで、この培地を0.03%のティオフィリ
ン(シグマ社製)を含む新しいイーグルMEM培地(6
ml)に交換し、各ウェルに適当な量の試料溶液((2)
で得たR202株の菌体抽出物)を添加した後さらに3日間
培養した。培養終了後、培地を捨てて各ウェルに1mlの
生理食塩水を加え、スクレーパーを用いてウェルの底面
に付着している細胞をかきとるように懸濁させた。次
に、ピペットを用いて該細胞懸濁液をマイクロ遠心チュ
ーブ(1.5ml容量、エッペンドルフ社製)に移し、遠心分
離(10,000×g 、15分間)した。
Then, this medium was replaced with a new Eagle MEM medium (6%) containing 0.03% of theophylline (manufactured by Sigma).
ml) and replace each well with an appropriate amount of sample solution ((2)
The cell extract of the R202 strain obtained in step 1) was added, and the mixture was further cultured for 3 days. After completion of the culture, the medium was discarded, 1 ml of physiological saline was added to each well, and the cells attached to the bottom of the well were suspended by scraping with a scraper. Next, the cell suspension was transferred to a microcentrifuge tube (1.5 ml volume, manufactured by Eppendorf) using a pipette and centrifuged (10,000 xg, 15 minutes).

【0028】一方、対照として、試料溶液の代わりに滅
菌水を添加して上記同様の試験を行った。また、細胞の
白色化を比較するための実験区として、試料溶液の代わ
りに2%L−アスコルビン酸水溶液を (a)60μl、(b)15
0μl、(c)300μl添加し、上記同様の試験を行った。
On the other hand, as a control, sterilized water was added instead of the sample solution, and the same test as above was conducted. In addition, as an experimental section for comparing whitening of cells, 2% L-ascorbic acid aqueous solution (a) 60 μl, (b) 15 was used instead of the sample solution.
0 μl and (c) 300 μl were added, and the same test as above was conducted.

【0029】次に、ペレットとなった細胞の白色化の度
合を目視で比較し、メラニン生成抑制効果の判定を行っ
た。その際、対照実験区(滅菌水添加区)の細胞の白色
の度合を「−」、L−アスコルビン酸を添加した比較実
験区の細胞の白色の度合をそれぞれ (a):「+」、
(b):「++」、 (c):「+++」として、試料溶液を
添加した場合の細胞の白色の度合が−、+、++、++
+のどれに当てはまるかを目視で判断し、試料溶液のメ
ラニン生成抑制効果の強さとして4段階の判定を行っ
た。なお、その結果は表2に示した。
Next, the degree of whitening of the pelletized cells was visually compared to determine the melanin production inhibitory effect. At that time, the degree of whiteness of cells in the control experiment group (sterile water addition group) was “−”, and the degree of whiteness of cells in the comparative experiment group to which L-ascorbic acid was added was (a): “+”,
(b): "++", (c): "++++", the degree of whiteness of the cells when the sample solution was added was-, +, ++, ++
It was visually judged which of + was applied, and the strength of the melanin production inhibitory effect of the sample solution was evaluated in four stages. The results are shown in Table 2.

【表2】 [Table 2]

【0030】(5)ラクトバチルス属乳酸菌体抽出物の
活性酸素消去効果の測定試験 活性酸素消去効果の測定はスーパーオキサイド・ディス
ムターゼ(SOD)の活性測定法のうち、チトクローム
Cを用いる方法に準じて行った。
(5) Measurement test of active oxygen scavenging effect of Lactobacillus sp. Lactic acid bacterium extract The active oxygen scavenging effect is measured according to the method using cytochrome C in the superoxide dismutase (SOD) activity measuring method. went.

【0031】まず、分光光度計用キュベット(4ml 容
量、光路 1cm)に試料溶液((2)で得たR202株の菌体
抽出物)を0.01mlから 1mlの範囲で入れ、このときの試
料溶液の量をAmlとした。次に、100mM トリス塩酸緩衝
液(pH 7.8)を(2.7−A)ml、1mM チトクロームC溶
液(上記トリス塩酸緩衝液に溶解したもの)を0.1ml 、
キサンチンオキシダーゼ溶液(ベーリンガーマンハイム
社製、製品番号110434を上記トリス塩酸緩衝液で80培に
希釈したもの)を 0.1ml、および15mMキサンチン溶液
(0.025 規定NaOH溶液に溶解したもの)を0.1ml 加
え、撹拌した。撹拌後、30℃の恒温キュベットホルダー
をセットしている分光光度計により、 550nmの吸光度の
変化(増加)を測定し、吸光度の増加速度の初速をVと
した。
First, the sample solution (the cell extract of the R202 strain obtained in (2)) was put in a cuvette for spectrophotometer (4 ml volume, optical path 1 cm) in the range of 0.01 ml to 1 ml. Was designated as Aml. Next, 100 mM Tris-HCl buffer (pH 7.8) (2.7-A) ml, 1 mM Cytochrome C solution (dissolved in the above Tris-HCl buffer) 0.1 ml,
Add 0.1 ml of xanthine oxidase solution (Boehringer Mannheim, product number 110434 diluted to 80 media with Tris-HCl buffer) and 0.1 ml of 15 mM xanthine solution (dissolved in 0.025N NaOH solution) and stir. did. After stirring, the change (increase) in the absorbance at 550 nm was measured with a spectrophotometer equipped with a 30 ° C. constant temperature cuvette holder, and the initial rate of the increase in absorbance was V.

【0032】また、活性酸素消去作用を比較するための
実験として、試料溶液の代わりにスーパーオキサイド・
ディスムターゼ(SOD)溶液(シグマ社製、製品番号
S-2515を上記トリス塩酸緩衝液で希釈し、終濃度を10活
性単位/mlとなるように調製したもの)についても上記
同様に550nm の吸光度の変化(増加)を測定し、吸光度
の増加速度の初速Vを求めた。
Further, as an experiment for comparing the active oxygen scavenging action, superoxide.
Dismutase (SOD) solution (manufactured by Sigma, product number
S-2515 was diluted with the above-mentioned Tris-HCl buffer to a final concentration of 10 activity units / ml, and the change (increase) in absorbance at 550 nm was measured in the same manner as above, and the rate of increase in absorbance was measured. The initial speed V was calculated.

【0033】一方、比較として、試料溶液の代わりにス
ーパーオキサイド・ディスムターゼ(SOD)溶液(シ
グマ社製:製品番号S−2515を上記トリス塩酸緩衝液で
希釈し、終濃度を10活性単位/mlとなるように調製した
もの)についても上記同様に550nm の吸光度の変化(増
加)を測定し、吸光度の増加速度の初速をVo とした。
On the other hand, as a comparison, instead of the sample solution, a superoxide dismutase (SOD) solution (manufactured by Sigma: product number S-2515 was diluted with the above-mentioned Tris-HCl buffer solution to give a final concentration of 10 activity units / ml. Was prepared in the same manner as above), the change (increase) in the absorbance at 550 nm was measured in the same manner as above, and the initial rate of increase in the absorbance was Vo.

【0034】上記測定したVおよびVo から試料溶液の
活性酸素消去率を算出した。なお、活性酸素消去率の算
出は、以下の計算式を用いて行い、その結果を表3に示
した。 活性酸素消去率(%)=(1−V/Vo )×100
The active oxygen scavenging rate of the sample solution was calculated from the above measured V and Vo. The active oxygen scavenging rate was calculated using the following formula, and the results are shown in Table 3. Active oxygen scavenging rate (%) = (1-V / Vo) × 100

【表3】 上記結果から、25μlの試料溶液はSODとして4活性
単位以上を含むと判定された。
[Table 3] From the above results, it was determined that 25 μl of the sample solution contained 4 activity units or more as SOD.

【0035】(6)化粧水の組成 (2)で得たラクトバチルス属乳酸菌体抽出物を用い、
以下に示すような配合の化粧料を製造することができ
る。 (重量%) ・菌体抽出物 1 ・グリセリン 5 ・ポリオキシエチレンソルビタンモノラウレート 1.5 ・エタノール 10 ・香料 適量 ・防腐剤 適量 ・色素 適量 ・精製水 適量
(6) Composition of lotion Using the Lactobacillus lactic acid bacterium extract obtained in (2),
It is possible to produce a cosmetic having the following composition. (Wt%) ・ Cell extract 1 ・ Glycerin 5 ・ Polyoxyethylenesorbitan monolaurate 1.5 ・ Ethanol 10 ・ Perfume proper amount ・ Preservative proper amount ・ Dye proper amount ・ Purified water proper amount

【0036】[0036]

【発明の効果】ケフィア粒より分離されたラクトバチル
ス属に属する乳酸菌の菌体から溶媒によって抽出される
抽出物は、優れたチロシナーゼ活性抑制効果、ならびに
メラノーマ細胞における優れたメラニン生成抑制効果、
および活性酸素消去効果を有しており、この抽出物を配
合した化粧料は、優れた皮膚美白効果および活性酸素消
去効果を発揮する。
EFFECT OF THE INVENTION An extract extracted from a lactic acid bacterium belonging to the genus Lactobacillus separated from kefir grains with a solvent has an excellent tyrosinase activity inhibitory effect, and an excellent melanin production inhibitory effect in melanoma cells,
And has an active oxygen scavenging effect, and a cosmetic containing this extract exhibits an excellent skin whitening effect and an active oxygen scavenging effect.

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】 ケフィア粒から分離したラクトバチルス
属乳酸菌の菌体抽出物を配合したことを特徴とする化粧
料。
1. A cosmetic comprising a lactobacillus lactic acid bacterium bacterial cell extract separated from kefir grains.
JP35386191A 1991-12-18 1991-12-18 Cosmetic Pending JPH05163134A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP35386191A JPH05163134A (en) 1991-12-18 1991-12-18 Cosmetic

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP35386191A JPH05163134A (en) 1991-12-18 1991-12-18 Cosmetic

Publications (1)

Publication Number Publication Date
JPH05163134A true JPH05163134A (en) 1993-06-29

Family

ID=18433724

Family Applications (1)

Application Number Title Priority Date Filing Date
JP35386191A Pending JPH05163134A (en) 1991-12-18 1991-12-18 Cosmetic

Country Status (1)

Country Link
JP (1) JPH05163134A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2116201A1 (en) * 1995-08-23 1998-07-01 Mendez Uruena Francisco J Hair regenerator
WO2001019324A1 (en) * 1999-09-14 2001-03-22 Isao Horiuchi Cosmetics
JP2006124290A (en) * 2004-10-27 2006-05-18 Yonezawa Biru System Service:Kk Microorganism cultured material obtained by culture medium containing mugwort extract as main ingredient and product using the same
JP5048246B2 (en) * 2003-08-26 2012-10-17 日本ケフィア株式会社 Internal composition for skin care
CN113181086A (en) * 2021-04-06 2021-07-30 厦门医学院 Application of saussurea involucrata bacteria fermentation product in inhibiting tyrosinase activity and melanin generation

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2116201A1 (en) * 1995-08-23 1998-07-01 Mendez Uruena Francisco J Hair regenerator
WO2001019324A1 (en) * 1999-09-14 2001-03-22 Isao Horiuchi Cosmetics
JP5048246B2 (en) * 2003-08-26 2012-10-17 日本ケフィア株式会社 Internal composition for skin care
JP2006124290A (en) * 2004-10-27 2006-05-18 Yonezawa Biru System Service:Kk Microorganism cultured material obtained by culture medium containing mugwort extract as main ingredient and product using the same
CN113181086A (en) * 2021-04-06 2021-07-30 厦门医学院 Application of saussurea involucrata bacteria fermentation product in inhibiting tyrosinase activity and melanin generation
CN113181086B (en) * 2021-04-06 2023-11-17 厦门医学院 Application of saussurea involucrata fermentation product in inhibiting tyrosinase activity and melanin generation

Similar Documents

Publication Publication Date Title
KR102032546B1 (en) Cosmetic comoposition for antibacterial comprising Lactobacillus plantarum culture
KR101425716B1 (en) Novel Strain of Lactobacillus fermentum spp., Cosmetic Composition Using the same and Preparation Method thereof
WO2010013852A1 (en) Cosmetic composition for anti-aging of the skin comprising phaseolus radiatus seed extracts by fermentation and enzyme treatment
TWI734048B (en) Cosmetic composition for improving skin wrinkles comprising lactobacillus plantarum culture
JPH0710734A (en) Cosmetic
KR101737940B1 (en) Composition of skin external application containing fermented soybean leaves extract
KR101040508B1 (en) Cosmetic Composition for Anti-aging and moisturizing of the Skin Comprising Phaseolus radiatus seed extracts by fermentation and enzyme treatment
JPH05163134A (en) Cosmetic
JP4547320B2 (en) Hair nourishing agent
KR102026597B1 (en) Cosmetic composition for skin whitening comprising a mixture of lactic acid bacteria culture
KR20210046195A (en) Cosmetic composition for improving skin wrinkle comprising extract of clematic florida flower
KR100467068B1 (en) Lactococcus lactis CBT-19, manufacturing method of the culture broth concentration and the cosmetic preparation
KR102155716B1 (en) A carrot fermentation method using lactobacillus plantarum ami-1103 strain
KR20190037436A (en) Cosmetic composition including fermented water lily extract and method for manufacturing the same
KR102039883B1 (en) Cosmetic composition comprising fermented coconut sugar extract and manufacturing method thereof
KR20110105243A (en) Cosmetic composition for the skin whitening comprising phaseolus radiatus seed extracts by fermentation and enzyme treatment
KR102640916B1 (en) A cosmetic composition comprising mixed culture strain of ligilactobacillus luminis lmt16-11, culture fluid, or culture fluid extract thereof as active ingredient
JPH05194258A (en) Inhibitor of melanin pigment synthesis
JP3195044B2 (en) Cosmetics
KR102499330B1 (en) Cosmetic composition containing culture with complex strains separated from kombucha for skin barrier reinforcement
KR102482157B1 (en) Cosmetic composition comprising the mixed culture broth of lactobacilli containing sulfur amino acids for skin stress improvement
KR102652401B1 (en) Cosmetic composition comprising a double ferment of Kunzea ericoides extract
JPH05331036A (en) Melanism inhibitor and cosmetic containing the same
US7115721B2 (en) Microorganism, its product and utilization thereof
JPH0710736A (en) Cosmetic